Pub Date : 2026-03-01Epub Date: 2026-02-03DOI: 10.1016/j.ijrobp.2025.12.002
Frank A. Giordano M.D.
{"title":"Heat or Healing? Dealing With “Something That Looks Like Progression” of Brain Metastases","authors":"Frank A. Giordano M.D.","doi":"10.1016/j.ijrobp.2025.12.002","DOIUrl":"10.1016/j.ijrobp.2025.12.002","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"124 3","pages":"Page 572"},"PeriodicalIF":6.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146102654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-02-03DOI: 10.1016/j.ijrobp.2025.12.004
Christina Tsien MD, FRCP, FASTRO, Kevin Petrecca MD, PhD, FRSC
{"title":"Ahead of the Curve: Early Recognition and Effective Management of Radiation Necrosis","authors":"Christina Tsien MD, FRCP, FASTRO, Kevin Petrecca MD, PhD, FRSC","doi":"10.1016/j.ijrobp.2025.12.004","DOIUrl":"10.1016/j.ijrobp.2025.12.004","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"124 3","pages":"Page 573"},"PeriodicalIF":6.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146102631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-02-03DOI: 10.1016/j.ijrobp.2025.11.055
Christina C. Huang MD, Chris R. Kelsey MD
{"title":"In Reply to Oertel et al","authors":"Christina C. Huang MD, Chris R. Kelsey MD","doi":"10.1016/j.ijrobp.2025.11.055","DOIUrl":"10.1016/j.ijrobp.2025.11.055","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"124 3","pages":"Pages 880-881"},"PeriodicalIF":6.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146102687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-02-03DOI: 10.1016/j.ijrobp.2025.10.032
Cas Stefaan Dejonckheere MD , Julian Philipp Layer MD
{"title":"Too Hot to Handle? Navigating the Dilemma of Radiation Necrosis After Stereotactic Radiosurgery for Brain Metastases","authors":"Cas Stefaan Dejonckheere MD , Julian Philipp Layer MD","doi":"10.1016/j.ijrobp.2025.10.032","DOIUrl":"10.1016/j.ijrobp.2025.10.032","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"124 3","pages":"Pages 570-571"},"PeriodicalIF":6.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146102854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-10-14DOI: 10.1016/j.ijrobp.2025.09.058
Tian-You Zhan MD , Tao Zhang MD , Wen-Qing Wang MD , Lei Deng MD , Yi-Rui Zhai MD , Wen-Bin Yan MD , Xin Wang MD , Jian-Yang Wang MD , Wen-Yang Liu MD , Ming-Hui Li PhD , Qin-Fu Feng MD , Ji-Ma Lv MD , Ze-Fen Xiao MD , Dong-Fu Chen MD , Jun-Ling Li MD , Lv-Hua Wang MD , Jun Liang MD , Hong Ge MD , Jian-Rong Dai PhD , Kuo Men PhD , Zong-Mei Zhou MD
Purpose
Simultaneous integrated dose reduction (SDR) radiation therapy (SDR-RT) with a definitive dose to the gross tumor volume (GTV) and a relatively lower dose to the clinical target volume (CTV) might be beneficial in improving normal tissue sparing with low toxicity. We aimed to compare the efficacies of SDR-RT and conventional fractionated radiation therapy (CF-RT) for limited-stage small cell lung cancer (LS-SCLC).
Methods and Materials
Eligible patients with LS-SCLC were 1:1 randomized to receive CF-RT (60 Gy in 30 once-daily fractions over 6 weeks for both CTV and GTV) or SDR-RT (50 Gy for CTV and 60 Gy for GTV in 28 once-daily fractions over 5.5 weeks) along with 4 to 6 cycles of chemotherapy. The primary endpoint was progression-free survival (PFS) rate in the intention-to-treat population, whereas the secondary endpoints were overall survival rate and adverse event incidence.
Results
Between February 2017 and March 2023, 336 patients randomly received either SDR-RT (n = 165) or CF-RT (n = 171). Over a median follow-up of 56 months, the 2- and 5-year PFS rates in the intention-to-treat analysis were, respectively, 42.0% and 31.9% with SDR-RT, and 40.7% and 30.5% with CF-RT (P = .015 for noninferiority). The between-group differences in overall survival, locoregional PFS, and locoregional recurrence rates were nonsignificant. Compared with CF-RT, SDR-RT was associated with lower median values of V20 (21.0% vs 22.8%) and Dmean (12.1 vs 13.4 Gy) of the bilateral lungs (both P < .001). Acute grade ≥3 toxicities and radiation pneumonitis incidence were lower with SDR-RT than that with CF-RT (54.5% vs 66.9%, P = .020; 2.4% vs 7.7%, P = .027).
Conclusions
Compared with CF-RT, SDR-RT led to similar survival and less acute adverse events. SDR-RT may be considered as a more protective approach for LS-SCLC treatment.
背景:同时综合减剂量(SDR)放疗(SDR- rt)对肿瘤总体积(GTV)的确定剂量和相对较低的临床靶体积(CTV)剂量可能有助于改善正常组织保留和低毒性。这项随机对照试验(SDR-RT试验)比较了SDR-RT和传统分割放疗(CF-RT)治疗有限期小细胞肺癌(LS-SCLC)的疗效。方法:符合条件的LS-SCLC患者以1:1的比例随机接受CF-RT (CTV和GTV每天30次,每次60 Gy,持续6周)或SDR-RT (CTV每天50 Gy, GTV每天28次,每次60 Gy,持续5.5周)以及4-6个周期的化疗。主要终点是意向治疗(ITT)人群的无进展生存(PFS)率,而次要终点是总生存(OS)率和不良事件发生率。结果:在2017年2月至2023年3月期间,336名患者随机接受了SDR-RT (n = 165)或CF-RT (n = 171)。在56个月的中位随访中,ITT分析的2年和5年PFS分别为SDR-RT组42.0%和31.9%,CF-RT组40.7%和30.5% (P = 0.015,非劣效性)。组间OS、局部区域PFS和局部区域复发率差异无统计学意义。与CF-RT相比,SDR-RT与双肺V20中位值(21.0%比22.8%)和Dmean(12.1比13.4 Gy)较低相关(P均< 0.001)。急性≥3级毒性反应和放射性肺炎发生率,SDR-RT组低于CF-RT组(54.5% vs 66.9%, P = 0.020;2.4% vs 7.7%, P = 0.027)。结论:与CF-RT相比,SDR-RT的生存期相似,急性不良事件较少。SDR-RT可能被认为是一种更具保护性的LS-SCLC治疗方法。试验注册:ClinicalTrials.gov, NCT04500145。
{"title":"Simultaneous Integrated Dose Reduction Radiation Therapy Versus Conventional Fractionated Radiation Therapy With Chemotherapy for Limited-Stage Small Cell Lung Cancer in the Modern Treatment Era: A Phase 3, Randomized Clinical Trial (SDR-RT trial)","authors":"Tian-You Zhan MD , Tao Zhang MD , Wen-Qing Wang MD , Lei Deng MD , Yi-Rui Zhai MD , Wen-Bin Yan MD , Xin Wang MD , Jian-Yang Wang MD , Wen-Yang Liu MD , Ming-Hui Li PhD , Qin-Fu Feng MD , Ji-Ma Lv MD , Ze-Fen Xiao MD , Dong-Fu Chen MD , Jun-Ling Li MD , Lv-Hua Wang MD , Jun Liang MD , Hong Ge MD , Jian-Rong Dai PhD , Kuo Men PhD , Zong-Mei Zhou MD","doi":"10.1016/j.ijrobp.2025.09.058","DOIUrl":"10.1016/j.ijrobp.2025.09.058","url":null,"abstract":"<div><h3>Purpose</h3><div>Simultaneous integrated dose reduction (SDR) radiation therapy (SDR-RT) with a definitive dose to the gross tumor volume (GTV) and a relatively lower dose to the clinical target volume (CTV) might be beneficial in improving normal tissue sparing with low toxicity. We aimed to compare the efficacies of SDR-RT and conventional fractionated radiation therapy (CF-RT) for limited-stage small cell lung cancer (LS-SCLC).</div></div><div><h3>Methods and Materials</h3><div>Eligible patients with LS-SCLC were 1:1 randomized to receive CF-RT (60 Gy in 30 once-daily fractions over 6 weeks for both CTV and GTV) or SDR-RT (50 Gy for CTV and 60 Gy for GTV in 28 once-daily fractions over 5.5 weeks) along with 4 to 6 cycles of chemotherapy. The primary endpoint was progression-free survival (PFS) rate in the intention-to-treat population, whereas the secondary endpoints were overall survival rate and adverse event incidence.</div></div><div><h3>Results</h3><div>Between February 2017 and March 2023, 336 patients randomly received either SDR-RT (n = 165) or CF-RT (n = 171). Over a median follow-up of 56 months, the 2- and 5-year PFS rates in the intention-to-treat analysis were, respectively, 42.0% and 31.9% with SDR-RT, and 40.7% and 30.5% with CF-RT (<em>P</em> = .015 for noninferiority). The between-group differences in overall survival, locoregional PFS, and locoregional recurrence rates were nonsignificant. Compared with CF-RT, SDR-RT was associated with lower median values of V20 (21.0% vs 22.8%) and Dmean (12.1 vs 13.4 Gy) of the bilateral lungs (both <em>P</em> < .001). Acute grade ≥3 toxicities and radiation pneumonitis incidence were lower with SDR-RT than that with CF-RT (54.5% vs 66.9%, <em>P</em> = .020; 2.4% vs 7.7%, <em>P</em> = .027).</div></div><div><h3>Conclusions</h3><div>Compared with CF-RT, SDR-RT led to similar survival and less acute adverse events. SDR-RT may be considered as a more protective approach for LS-SCLC treatment.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"124 3","pages":"Pages 692-701"},"PeriodicalIF":6.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145307933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-02-03DOI: 10.1016/j.ijrobp.2025.11.015
Pierre Loap MD, Youlia Kirova MD
{"title":"In Reply to Liu et al","authors":"Pierre Loap MD, Youlia Kirova MD","doi":"10.1016/j.ijrobp.2025.11.015","DOIUrl":"10.1016/j.ijrobp.2025.11.015","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"124 3","pages":"Pages 877-878"},"PeriodicalIF":6.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146102526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-02-03DOI: 10.1016/j.ijrobp.2025.10.013
Maria Gebre-Medhin MD, PhD , Gabriel Adrian MD, PhD
{"title":"Circulating Tumor DNA in Human Papilloma Virus-Positive Oropharyngeal Squamous Cell Carcinoma—Are We Ready to Individualize Treatment?","authors":"Maria Gebre-Medhin MD, PhD , Gabriel Adrian MD, PhD","doi":"10.1016/j.ijrobp.2025.10.013","DOIUrl":"10.1016/j.ijrobp.2025.10.013","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"124 3","pages":"Pages 686-691"},"PeriodicalIF":6.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146102652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-02-03DOI: 10.1016/j.ijrobp.2025.11.014
Matthias May MD, PhD, Oscar R. Brouwer MD, PhD, Laura Elst MD, Maarten Albersen MD, PhD
{"title":"In Regard to Ka et al.","authors":"Matthias May MD, PhD, Oscar R. Brouwer MD, PhD, Laura Elst MD, Maarten Albersen MD, PhD","doi":"10.1016/j.ijrobp.2025.11.014","DOIUrl":"10.1016/j.ijrobp.2025.11.014","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"124 3","pages":"Pages 868-869"},"PeriodicalIF":6.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146102404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}